Human Primary Cell Screening Assays
Research type
Research Study
Full title
Understanding how novel drugs affect a variety of conditions including oncology, immunology and inflammation to identify potential therapeutic targets.
IRAS ID
270936
Contact name
Clare Doris
Contact email
Sponsor organisation
Aquila BioMedical Ltd
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Aquila Biomedical provide highly specialised preclinical services with a focus on Immuno-oncology, Multiple Sclerosis, Autoimmune Disease, Immunology and Analgesia. A key feature of Aquila is the partnering of services with world-leading academics in the field to provide expert advice and interpretation of data.
Aquila currently offer various in vitro and in vivo animal models in addition to a range of human immune cell assays. These can be used to screen client compounds to identify potential drug therapies.REC name
West Midlands - Black Country Research Ethics Committee
REC reference
19/WM/0260
Date of REC Opinion
23 Aug 2019
REC opinion
Favourable Opinion